title: New Methodologies in the Molecular Monitoring of CML.
abstract: In chronic myeloid leukemia (CML), the BCR-ABL fusion gene is both the therapeutic target of tyrosine kinase inhibitors and the indisputable direct marker of disease burden. Thus, sensitive assays for BCR-ABL now drive therapeutic options and are good surrogates for short- and long-term outcomes. Because CML is such an ideal model, new methods are arising that should make testing in CML faster, more reliable, and reach a greater sensitivity. These methods should be able to be transferred to other hematological malignancies that have mutation markers.
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, G7-910, Seattle, WA, 98109, USA. cyeung@fredhutch.org.
authors.forename: Cecilia C S
authors.initials: CC
authors.lastname: Yeung
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, G7-910, Seattle, WA, 98109, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Egan
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, G7-910, Seattle, WA, 98109, USA.
authors.forename: Jerald
authors.initials: J
authors.lastname: Radich
mesh_terms: D004247:DNA / Q000235:genetics; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000378:metabolism*; D009154:Mutation; D016133:Polymerase Chain Reaction
chemical_list: D004247:DNA
keywords: BCR-ABL1 transcript levels molecular diagnostics; Chronic myeloid leukemia; Monitoring